COVID-19 rapid test

pneumoniaMERSIgG

In 2019, a new coronavirus disease was reported in Wuhan, China. This disease subsequently affected a majority of countries in the world causing significant lung damage and respiratory failure. The pathogen has been identified as a coronavirus similar to that of SARS and MERS. He was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical manifestations are systemic symptoms such as fever and fatigue, accompanied by dry cough and dyspnea which can quickly develop into severe pneumonia and acute respiratory failure and can be fatal. The diagnosis is currently carried out by RT-qPCR techniques which have variations depending on the country but which very strongly depend on the quality of the nasopharyngeal swab (low presence or absence of virus). According to the patients and to the period of infection, the virus is localized in the lungs and not in the nose or throat . For various reasons, the RT-qPCR test is not very suitable for testing a large population: - The quality of the sample easily compromised - More than 30% false negatives in some studies in real situations - The technical heaviness (4 to 6 H) of the RT-qPCR COVID-19 assay. - Its high cost (20 to 56 Euros per test in France and much more in other countries). In order to meet the growing demand for rapid and reliable detection solutions for SARS-CoV-2 coronavirus infection, Spartacus-Biomed presents the LFA COVID-19 IgG & IgM Rapid Test Device as a diagnostic aid.